Author: Customer Service

The Assigned FDA Approval Goal Date is June 4, 2025 TORONTO, March 11, 2025 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company hyper-focused on the commercialization of Ketamine, is pleased to announce today that the Company has received an Amendment Acknowledgement Letter (“AAL”) from the U.S. Food and Drug Administration (“FDA”) for its New Drug Application for Ketamine. In the AAL, the FDA determined this is a minor amendment, meets the criteria for priority review, and assigned an approval goal date of June 4, 2025. Fabio Chianelli, Chairman and CEO of PharmaTher, commented: “I am very pleased with the new FDA approval goal date of June 4, 2025 for our Ketamine drug. We are focused on solving the shortage issue of Ketamine and becoming...

Strategic name change reflects company’s evolution and global market presence ORLANDO, Fla., March 11, 2025 (GLOBE NEWSWIRE) — Abacus Life (NASDAQ: ABL), a leader in the alternative asset management space, today announced it has rebranded to Abacus Global Management (abacusgm.com), effective immediately. The new name better reflects the company’s expanded global presence and comprehensive suite of financial services spanning life solutions, asset management, wealth management, and technology solutions. The company’s focus on innovative technology represents a core and growing part of its business strategy going forward. “Our evolution to Abacus Global Management represents a significant milestone in our company’s journey, to revolutionize financial services though expert asset management leveraging advanced technology and to deliver...

Funded by a grant from the Roblox Community Fund, AVID’s Creator Planet integrates with key educational standards and includes free classroom resources for teachers and students SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) — Today, AVID (Advancement Via Individual Determination), a leader in closing the opportunity gap for students, and Super League (Nasdaq: SLE), a leader in redefining the gaming industry as a media channel, announce the launch of AVID Creator Planet, an educational adventure on Roblox designed for students ages 13+ to learn valuable executive function and durable skills in and out of the classroom. Funded by a grant from the Roblox Community Fund, AVID Creator Planet focuses on practicing durable skills such as problem-solving, critical thinking, collaboration, and communication. Each phase – from planning and...

NASHUA, N.H., March 11, 2025 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, 2024, after market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, March 19, 2025. Earnings call details are as follows: Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 174549Webcast: https://www.webcaster4.com/Webcast/Page/2879/52064 About iCAD, Inc. iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua,...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) —  Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that it has launched an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA). The enhanced clonoSEQ assay, which incorporates an optimized DNA extraction methodology and maximizes sample input, delivers a 7-fold increase in sensitivity. The assay leverages...

FREMONT, Calif., March 11, 2025 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, today announced production shipments of its newest electric vehicle (EV) charger, the IQ® EV Charger 2, in 14 European markets. The IQ EV Charger 2 is a smart charger designed to work seamlessly with Enphase solar and battery systems or as a powerful standalone charger. With advanced energy management features, the charger empowers homeowners to maximize solar self-consumption, lower energy costs, and enjoy a smart, efficient EV charging experience. The IQ EV Charger 2 is now available in Norway, Germany, the United Kingdom (UK), France, the Netherlands, Sweden, Denmark, Switzerland, Austria, Belgium, Luxembourg, Italy,...